Description
Record date set for December 24, 2025 to determine shareholders eligible to participate in the buyback offer of Nectar Lifesciences Limited.
Summary
BSE has announced that Nectar Lifesciences Limited (Scrip Code: 532649) has fixed December 24, 2025 as the record date to determine the entitlement and names of equity shareholders eligible to participate in the company’s buyback offer. The stock will trade on an ex-entitlement basis from December 24, 2025 (Settlement No. DR-784/2025-2026).
Key Points
- Company: Nectar Lifesciences Limited (BSE Code: 532649)
- Record Date: December 24, 2025
- Purpose: Determine eligible shareholders for buyback participation
- Ex-Entitlement Date: December 24, 2025
- Settlement Number: DR-784/2025-2026
- Segment: Dematerialised Securities - Rolling Settlement
- Notice Number: 20251222-10
Regulatory Changes
No regulatory changes. This is a standard corporate action notification for a buyback offer.
Compliance Requirements
- Trading members must note the record date and ex-entitlement date
- Only shareholders holding shares as of December 24, 2025 will be eligible to participate in the buyback
- Shares will trade ex-entitlement from December 24, 2025
Important Dates
- December 22, 2025: Circular issued
- December 24, 2025: Record date for buyback eligibility
- December 24, 2025: Ex-entitlement trading begins (Settlement DR-784/2025-2026)
Impact Assessment
Market Impact: Medium - The buyback will affect Nectar Lifesciences shareholders who hold shares on the record date. Trading on ex-entitlement basis from December 24, 2025 may influence short-term price movements.
Investor Impact: Shareholders holding shares on December 24, 2025 will be eligible to participate in the tender offer. Those purchasing shares on or after the ex-entitlement date will not be eligible.
Operational Impact: Trading members need to ensure proper settlement and client communication regarding eligibility for the buyback offer.
Impact Justification
Standard corporate action affecting specific company shareholders. Medium impact limited to Nectar Lifesciences shareholders eligible for buyback participation.